The efficacy of Bacille Calmette-Guerin (BCG) against pulmonary tuberculosis (TB) in infants and adults varies from 0 to 80% in different studies. [1] [2] [3] [4] However, BCG is generally considered to protect against tuberculous meningitis and miliary TB among infants. 5, 6 When introduced in the 1930s, BCG vaccination was sometimes considered to have a non-TB-related beneficial effect on survival in children. 7 Recent findings have also suggested that BCG may have a non-specific beneficial effect on childhood survival: 8-11 BCG vaccination was associated with a decrease in infant mortality of 45% in rural Guinea-Bissau 9 and of 40% in Benin. 11 Whether BCG affects specific diseases remains uncertain, but in a case-control study from Brazil, BCG reduced the risk of death from pneumonia by 50%. 10 The implications of a BCG scar in TB protection and vaccine efficacy has often been discussed, 12-16 but it is still doubtful whether scar development is linked to the immunological
response to BCG 14 in spite of studies indicating this. 17 The immunological relationship between scar and possible nonspecific effects of BCG has not been studied. However, considering the importance of vaccination technique for scar development (injected dose 18 and route of administration 19 ), we assumed that if BCG vaccination has a beneficial nontargeted effect, this effect would be strongest among children who had responded to vaccination with a scar. Consistently, we observed in Guinea-Bissau that among BCG-vaccinated children, a BCG scar was related to better child survival, 20 and in a hospital study from Malawi a BCG scar was related to less skin infections and sepsis. 17 The plausibility of BCG being a non-specific immune stimulator has been strengthened by recent studies showing that BCG produces a Th1-biased immune response at birth. 21 BCG has also been shown to reduce atopy 22 and cutaneous anergy 23 and to stimulate both cellular 23 and antibody responses 24 to unrelated antigens.
To pursue this pattern, we screened children Ͻ5 years of age in Bissau for BCG scars to examine whether better survival for children with a BCG scar was a reproducible observation. We were able to exclude children exposed to TB at home, since we have had a continuous TB surveillance system in the study area. We conducted verbal autopsies (VAs) for children who died in the present and a previously presented cohort study 20 to identify possible differences in the major causes of death for children with and without a BCG scar.
Method and subjects
The study population consisted of residents in four districts of Bissau, the capital of Guinea-Bissau. The districts Bandim I, Bandim II, Belem, and Mindará have been followed by the demographic surveillance of the Bandim Health Project (BHP) since 1978, 1984, 1984 , and 1994, respectively. 25 Deaths were ascertained by BHP through the routine household visits every third month for 0 to 3-year-old children or through the census system with at least yearly visits for older children.
Two partly overlapping cohorts were used to describe the mortality pattern for children with or without a BCG scar and to describe specific causes of mortality:
Cohort A. As part of a two-dose measles vaccine trial, children were recruited at 6 months of age and at the same time screened for the presence of a BCG scar. Between November 1996 and May 1998 we included 1813 children (1676 with scar, 137 without scar) who were BCG-vaccinated at least 1 month before scar reading. As described elsewhere, 20 scar-positive children had a lower mortality than scar-negative children the following 12 months, the mortality ratio (MR) being 0.41 (95% CI 0.25-0.67).
Cohort B. Between January 1998 and October 1999, 1679 children between 3 months and 5 years of age were visited in their homes and examined for the presence of a BCG scar (1194 scar, 485 no scar). This was done as part of a scar survey, in which all houses in Bandim I and Bandim II were visited. The surveillance system was used to identify individuals in the households, and all individuals living in the study area who consented to take part in the study were assessed for vaccine scars. In the year following the scar reading, 1673 of the 1679 children were visited at least once to assess mortality while 6 (4 scar, 2 no scar) children were lost to follow-up. Of these 1673 children, 1617 (1159 scar, 458 no scar) had a documented BCG vaccination at least 1 month before scar reading. The other 56 children were either not vaccinated or the BCG status was unknown.
BCG vaccination
Information on vaccination status was obtained from the vaccination card, either at the time of scar assessment (cohort A) or through the routine surveillance system of the BHP (cohort B). In Bissau, the BCG vaccine is customarily given at birth or as soon as possible after the first health contact. BCG immunization was administered Monday to Friday at the central hospital and on Monday and Friday at the local health centre. Pasteur Mérieux, France, and Statens Serum Institut, Denmark, provided the BCG vaccine via the local Expanded Programme on Immunization (EPI). Following EPI recommendations, BCG was administered by a 0.05 ml (0.1 ml for children Ͼ1 year of age) intradermal injection in the left deltoid area. For the present study, children were considered BCGvaccinated if vaccinated at least 30 days before scar reading.
TB surveillance
Since May 1996, we have registered all cases of TB in the study area through a TB surveillance system. This was based on passive and active case finding, where all adult patients (у15 years) living in the study area reporting to a health centre with symptoms or signs of active TB were further investigated. In addition two nurses visited houses, where cases had been found, every third month to detect secondary cases. 26 Since all scar readings in the present study were done from 1996 onwards, we were able to control for exposure to TB in the household. As recommended by the International Union Against Tuberculosis and Lung Disease, 27 patients with clinical signs, symptoms, and X-ray changes compatible with active intrathoracic tuberculosis, but without positive bacteriological tests, were treated with antibiotics (co-trimoxazole or amoxicillin) and then re-evaluated clinically and also with a chest X-ray. If there was no improvement and suspicion remained, the patient was diagnosed as having presumed TB. In the present analysis, TB cases include both smear-positive and smear-negative patients with presumed TB. In order to assess the quality of the TB surveillance in the study area, VAs were performed for all deceased adults in the study area from 1996 to 1998. Only two persons who might have died of TB, but had not been diagnosed and treated, were found. 20 
Mortality
Overall mortality for children with a documented BCG vaccination before scar assessment was described for children in cohort B in the same manner as it has earlier been described in cohort A. 20 Of the 1617 children in cohort B with documented BCG vaccination at least 1 month before scar reading, 488 had also been included in cohort A. If they were enrolled in cohort B before cohort A (31 scar, 8 no scar), their follow-up was terminated in cohort B on the day of inclusion in cohort A. The 449 (416 scar, 33 no scar) children included in cohort A before being examined as part of the cohort B household survey were excluded from cohort B in order not to replicate results. If the scar status did not correlate between the two assessments made in the two different cohorts, the scar assessment relevant for the follow-up time was used. Children were included in the survival analysis on the day of scar reading or assessment of the vaccination card, whichever came last, and were excluded on the day of moving from the study area or 365 days after scar reading, whichever came first. One child (no scar) dying in an accident was excluded from the analysis. Thus, 1-year mortality from the time of scar reading and onward was described for 1167 (794 scar, 373 no scar) children in cohort B in a Cox regression analysis with age as underlying time (Figure 1) . A combined estimate of 1-year mortality for both cohort A and B was based on 2693 person years of observation, not replicating any follow-up time is also presented (Figure 1 ).
The survival analyses controlled for background factors with possible influence on child mortality including sex, year of birth (1993, 1994, 1995, , season of vaccination (rainy: July-November or dry:December-June), district of residence (Bandim 1 or Bandim 2), place of birth (home, the central hospital, or the Bandim health centre), electricity in house (yes or no), schooling of mother (0, 1-4 or у5 years), ethnic group (Pepel, or other ethnic group), and age at vaccination (0-30 days, 31 days or older). In univariable and multivariable Cox regression analyses, these background factors were tested for association with mortality in the joint cohort of A and B, and factors with a P-value of Ͻ0.20 in the multivariable analysis were adjusted for in all multivariable analyses. TB infection had no impact on the results in cohort A, 20 and to assess the possible impact of TB infection on our estimate in cohort B, we excluded 
Specific mortality as assessed by VA
Of the children with BCG vaccination at least one month before scar assessment, 488 children were included in both cohort A (1813) and B (1617) resulting in a total of 2942 children (2434 scar, 508 no scar) eligible for assessment of different causes of mortality for scar vs no scar. Within the year following scar reading 149 children died (116 scar, 33 no scar). A VA was developed on the basis of a standard VA recommended by WHO 28 and adjusted to the local culture and language through discussions and trials together with physicians and a midwife used to perform VA in the study area. 29, 30 Once the war was over in Guinea-Bissau, a Guinean physician conducted the VA by visiting the relatives of the deceased children between June 2000 and June 2002, the median time from death to interview being 2.4 years. In order to be considered a reliable informant to the VA, the relative had to have been a member in the same household as the deceased child during the time of the child's disease and death. Of the 149 deaths, we were able to conduct a VA for 77% (90 scar, 25 no scar); for the remaining 34 deaths (26 scar, 8 no scar), all close relatives had moved or died when screening started. The physician conducting the VA was blind to whether the child had had a BCG scar or not. When the 115 VAs were carried out, a group consisting of the interviewing doctor, a paediatrician and another medical doctor, being blind to scar status of the children, decided on one of the following diagnoses as probable primary cause of death; accident/war, anaemia, malnutrition, acute diarrhoea, chronic diarrhoea, pneumonia, malaria, measles, meningitis/encephalitis, other disease, fever unclassified and cause unclassified. To simplify presentation, we categorized the diagnoses that contributed Ͻ5% to the total causes of deaths as 'other disease/cause', except for one death caused by accident, which was excluded. The expert group deciding on the most probable cause of death took into consideration the whole patient history that could be derived from the VA interview, including duration of a number of symptoms, duration and kind of treatment provided or stopped, and diagnostic tests reported (such as a blood smear test for malaria). The causes of death contributing to у5% of the total number of deaths were: malaria (fever, convulsions, affected responses of the child), pneumonia (cough, difficult breathing, fast breathing, chest in-drawings), acute diarrhoea (liquid and watery stools Ͻ14 days, dehydration), chronic diarrhoea (liquid and watery stools у15 days), and meningitis/encephalitis (fever, stiff neck/bulging fontanelle). To demonstrate whether there was a different distribution of scar status among the dead children in whom we did not succeed in performing a VA, these deaths were presented as 'no VA'. We calculated the risk of dying from each specific disease, according to scar status in the year following scar assessment. This was done through a separate dataset for each diagnosis, where the event was death and where follow-up was terminated at death due to all other causes, thereby creating a cause-specific hazard function. 31 Hence, the risk of dying from a particular disease was described in different Cox regression analyses with age as underlying time, one for each major category of disease.
Statistical software
The analyses were done using Stata 7 for Microsoft Windows. 
Results

Scar distribution
Mortality
In a multivariable Cox regression analysis of both cohort A and B, sex and ethnic group were associated with mortality (P Ͻ 0.20, data available on request). During the 12 months following scar reading, 27 of the 1167 children died in cohort B (Table 2) . Adjusting for sex and ethnic group, there was lower mortality for children with a scar, the MR being 0.45 (95% CI 0.21-0.96) ( Table 2 ). Taking TB exposure into account, excluding 165 children from the survival analysis and shortening observation time for 30 children, the MR was 0.37 (95% CI 0.15-0.92) ( Table 2 ). The effect of having a BCG scar was not significantly different for boys and girls ( Table 2 ) (test of homogeneity P = 0.281).
Combining cohorts A and B, 148 children (116 scar, 32 no scar) died in the 12 months following scar reading, and having a BCG scar was associated with a MR of 0.43 (95% CI 0.28-0.65), adjusting for sex and ethnic group. The effect was largest for children examined in the first year of life (Figure 2 ). However, in spite of including only children examined after the first year of life, the MR was still 0.47 (95% CI 0.21-1.04) after adjusting for significant background factors.
Specific mortality as assessed by VA
There was no differential effect of having BCG scar for different causes of death (Table 3) . Adjusting for sex and ethnic group, a As part of a two-dose measles vaccine trial, children were recruited at 6 months of age and at the same time screened for the presence of a BCG scar. Scar-positive children had a lower mortality than scar-negative children in the following 12 months in this cohort, as described elsewhere 20 . b Between January 1998 and October 1999, 1617 children between 3 months and 5 years of age with a documented BCG vaccination at least 1 month before the scar reading were visited in their house and examined for the presence of a BCG scar. 17 ) and cohort B, as described in detail in the paper. Children were followed-up for 12 months after inclusion (scar reading) and age is the underlying time since mortality is highly dependent on age in these age groups. † After exclusion of one child due to death in an accident, as discovered by VA, 2434 children with a scar and 507 without a scan were followed-up for survival 12 months after scar assessment. the cause-specific mortality rate of malaria was significantly lower for children with a BCG scar than without: MR being 0.32 (95% CI 0.13-0.76). Even if deaths due to malaria were combined with deaths due to unclassified fever (as these might well be due to malaria), the mortality rate was still significantly lower for scar-positive children [MR 0.42 (95% CI 0.21-0.82)].
Discussion
In this study we have shown that the mortality in the year following scar assessment was more than halved for children with a BCG scar compared with children without (Table 2) . This is comparable with earlier findings. 20 The observation would suggest that it is important to monitor BCG scarring among children in high mortality areas. The general distribution of causes of deaths corresponded to what have been described previously from Guinea-Bissau. 29, 30 There were no major differences in the impact of BCG scarring for different causes of deaths. The present study had limited power to detect differences between causes of death due to the small number of children without a scar, but nothing suggested that such differences might be important. The numbers were too small for a comparison of the potential impact of BCG scarring on the distribution of causes of deaths in the two cohorts, but then again nothing indicated differences of importance between the cohorts (data available on request). The MR in the combined cohort for children with a BCG scar was significantly lower only for malaria, which was the largest group of deaths together with 'fever unclassified'. While reasoning about different effects of BCG on particular diseases, the limitation of the VA method in determining an exact cause of death should also be stressed. Even though the recall period was delayed due to the outbreak of civil war, the physician carrying out the VA did not find the relatives of the deceased child to have difficulties in remembering the events leading to the death of the child. This observation cannot be validated and despite maternal recall of death of children having been considered quite reliable even years after the child's death, 32 the delay is a potential limitation of the present study. Few studies on the validity of VA have been done, and the studies that have been made vary in method, setting and population and it has been reported that the method of VA varies in specificity and sensitivity for different causes of death. 33 Hence, the question of what diseases are most affected by having a BCG scar remains unsolved. However, in settings such as that of the present study, VA may often be the best method available and it is used to provide approximate values for relatively common causes of death. 28 We therefore believe that our study suggests that the effect of a BCG scar may be related to a general enhancement of the immune response to many infections rather than providing protection against specific infections. This possibility is supported by studies of the impact of vaccination status on the case-fatality rate at the paediatric ward in Bissau; nonspecific effects of measles and DTP vaccines were documented, but there were no differences in the causes of deaths for vaccinated and unvaccinated children. 34 There were differences in the prevalence of BCG scar between the two cohorts. These could presumably be explained by the different study procedures since scar assessment could vary between readers; in one study a medical doctor knowing the BCG vaccination status assessed the scar as part of a medical examination in a health centre while in the other study, trained research assistants performed the scar reading in the homes of the children often without access to the vaccination card of the child. BCG scar prevalence varies with age of vaccination and time of scar reading after vaccination. 12 For BCG vaccinations given within one month of birth, the prevalence of a recognizable BCG scar will decline over time. 13 This could only partly explain the lower prevalence of scarring in cohort B (Table 1) . Of the 44 children with a BCG scar despite no documented BCG vaccination, 20% were probably due to a rapid scar reaction since vaccination had taken place within 30 days before BCG scar assessment; the remaining were due to failure to mark BCG vaccination on the vaccination card, misclassification of BCG scar or misclassification of BCG vaccination while inspecting the vaccination card. Since BCG vaccination took place in different years for the different cohorts, the differences in scar prevalence may also be related to changes in vaccination technique, vaccine type, vaccinating nurse, or lack of BCG vaccine during certain periods, resulting in delayed vaccination; we have observed that all of these factors may have an impact on BCG scarring (authors' unpublished data).
When assessing the relationship between mortality and BCG scar responses, HIV-1 could be a major confounder considering that HIV-1 infection has been shown to suppress scar reaction to BCG. 35, 36 During the study period (1993-98), HIV-1 infection was increasing in the study area, from 0% in the late 80s 37 among individuals у15 years of age to 2.2% in 1996. 38 Expecting a vertical transmission rate of 25%, 39, 40 we estimate that Ͻ1% of the children may have been HIV-1-infected in the present study. Considering the numerous beneficial effects on survival with a BCG scar observed in our study and the relatively low prevalence of HIV-1 infection, we reason that even if HIV-1 infection may have had a modifying effect on our results, it could not explain the major survival benefit observed to be associated with a BCG scar. It was shown consistently in cohort A, that a positive tuberculin skin test (TST) was strongly associated with better survival in the 12 months following TST testing and that excluding deaths of children seropositive to HIV-1 did not change the estimates. 20 One could argue that the results of the present study may be skewed as early infant deaths (Ͻ3 months) were not included. However, this ought not to be so, unless BCG has a negative effect on survival for the weak and young children which recent findings indicate is not the case. 41 Also, since all children included in the survival analyses were BCG vaccinated, confounding due to healthier children being more likely to be vaccinated is not applicable. Instead, it could be speculated that the beneficial effect of having a BCG scar was merely a marker of some children having stronger immune responses and therefore better survival. However, our studies in Guinea-Bissau have clearly found that BCG scarring depends on type of vaccine and vaccination technique. Furthermore, BCG vaccination has been found to be associated with non-specific enhancement of both antibody and cellular immune responses. 23, 24 Hence, the beneficial effect may in fact be related to the immune response induced by a correctly given BCG vaccination. Future studies should examine the ability of scar-negative children to develop a scar through re-vaccination. This may well be possible since the lack of scarring could be a result of faulty vaccination technique. If the immune stimulation producing a scar, upon re-vaccination, is comparable with the stimulation producing a scar after a primary vaccination, re-vaccination of scar-negative children might reduce infant mortality substantially, depending on the prevalence of scarnegative children. Of interest is also the reason for scar-failure: clearly a child never developing a scar after BCG vaccination may differ from a child with a waned scar reaction. This is also a possible uncontrolled confounder in the present study, although probably d MR, as assessed by different Cox regression analyses for each cause of death, where age was underlying time, the event was death within one year after scar assessment from that particular disease. e MR adjusted for sex and ethnic group; risk factors associated (P Ͻ 0.20) with mortality in the total survival analysis of cohorts A and B.
f No VAs were carried through among these children, because all household members who had been present during the disease and death of the child had moved or died.
not of major importance considering the relatively low rate of waning of the scar reaction (Table 1) .
Larger studies relating BCG vaccination, BCG scar, and other markers of BCG vaccination to specific morbidity, immune profiles, and mortality are warranted in order to determine the immunological mechanisms involved and to assess possible modifications in the current vaccination programme. If BCG has non-specific beneficial effects it should be recommended to re-vaccinate children without a BCG scar, especially considering that the beneficial effect of a BCG scar on survival seems to persist through early childhood.
